Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx Wins Chinese Approval for Lung Cancer Liquid Biopsy CDx

NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved Amoy Diagnostics' SuperARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs, the company said today.

According to Xiamen, China-based AmoyDx, the real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples from patients with advanced or metastatic NSCLC. The test was CE-IVD marked in April.

"The development of liquid biopsy-based diagnostics in non-small cell lung cancer will transform the diagnostic workup of advanced-stage patients," Guangdong General Hospital Vice President Yi-long Wu said in a statement. "The ability to both isolate and genetically interrogate tumor DNA from a simple, minimally invasive test that can subsequently inform treatment decisions will benefit [both] ... physician and patient."

In 2016, AmoyDx partnered with Merck KGaA to develop a SuperARMS-based liquid biopsy test for metastatic colorectal cancer for the Chinese market.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.